Effect of Losartan discontinuation on treatment of anemia in hemodialysis patients

Not Applicable

Recruiting

• Conditions: Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease.; Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease; I13.11

• Registration Number: IRCT20190127042516N1
• Lead Sponsor: Islamic Azad University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 25 February 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

All hypertensive patients with ESRD on regular hemodialysis consist of 3 4-hours session per week.
Use of Losartan at least the last three months

Exclusion Criteria

Dosage alteration for rHuEPO, ferrous sulfate and Carnitine supplementation.
Serious infection leading hospitalization
Obvious bleeding
Transfusion
Surgery
CRP>10 mg/L
Serum Ferritin <100 ng/ml
Any alteration in hemodialysis dosage/time

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hemoglobin increment. Timepoint: Before intervention and 3 months after discontinuation of Losartan. Method of measurement: Cell Counter Mindry BC 3000Plus machine.